eli lilly tirzepatide vials Launches Additional Zepbound Vial Doses with New Pricing Plans Patients gain more weight-loss choices

Record-Setting Weight Loss in 68 Weeks The TRIUMPH-4 Phase 3 trial enrolled 445 adults with both obesity and knee osteoarthritis

Research published in diabetes care journals demonstrates that GLP-1 agonists add meaningful A1C reductions on top of metformin monotherapy, typically lowering A1C by an additional 0.5% to 1.5% while also promoting weight loss averaging 25 kg over 6 months

Scand J Prim Health Care 43(2): 448454

This decrease was observed greatest among those on higher doses, where virtually all high-dose patients reached the top of these values

March 25, 2024 Glucagon-like peptide-1 (GLP-1) drugs for diabetes and weight loss represent the new wave of blockbuster drugs